4DMT’s gene therapy reduced need for standard-of-care injections to treat age-associated vision loss

4D Molecular Therapeutics’ one-time gene therapy reduced the need for annual injections in patients with age-related blindness in a mid-stage trial.

The company on Wednesday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

New Name for Familiar Phenomenon: ‘Administrative Harm’

Clinicians have long understood that administrative decisions can cause harm, both to themselves and to their patients. Now, a term for the phenomenon is gaining

July 11, 2024

Accelerating Progress in Cardiac Care with AI-Enabled Analysis

Stuart Long, CEO, InfoBionic Cardiac Health is Top of Mind. The Quest to ‘Zero’ Avoidable Cardiac-Related Deaths Continues. Cardiac disease is one of the top

January 3, 2024

Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial | Psychedelic Invest

Clearmind Medicine Inc. announced that it has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use

March 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.